Lung adenocarcinoma architecture predicts survival

Lung adenocarcinoma architecture predicts survival

(HealthDay) -- A new method of classifying invasive pulmonary adenocarcinomas, based on the predominant architecture developed by the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS), is a stage-independent predictor of survival, according to research published online March 5 in the Journal of Clinical Oncology.

To evaluate the prognostic impact of the new IASLC/ATS/ERS adenocarcinoma classification system, Arne Warth, M.D., of the University Hospital Heidelberg in Germany, and colleagues conducted a retrospective study utilizing data regarding the predominant architecture and histomorphology of resected adenocarcinomas from 500 patients.

The researchers found that the overall survival of patients with each type of adenocarcinoma architecture was significantly different: 78.5 months for lepidic, 67.3 for acinar, 58.1 for solid, 48.9 for papillary, and 44.9 for micropapillary. When the patterns were grouped, the differences were more pronounced: pattern groups 1, 2, and 3 had survival of 78.5, 67.3, and 57.2 months, respectively. Similar between-group differences were observed for patient disease-specific, disease-free, and overall survival. The prognostic value of these pattern groups was independent of adenocarcinoma stage and therapy used, but was influenced by adjuvant chemoradiotherapy. There was a close association between the predominant pattern and the risk of developing nodal metastases.

"Besides all recent molecular progress, architectural grading of pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS scheme is a rapid, straightforward, and efficient discriminator for and may support patient stratification for adjuvant chemoradiotherapy," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.